Niraparib (also formerly known as MK-4827) is a novel, highly selective, and orally available PARP-1 and PARP-2 small molecule drug developed by Tesaro, approved by FDA in 2017 to treat ovarian cancer (Ison et al., 2018). This evidence concerns the gene PARP1 and ovarian carcinoma.